



This document is a postprint version of an article published in Journal of Dairy Science © American Dairy Science Association®, 2020, after peer review. To access the final edited and published work see <https://doi.org/10.3168/jds.2019-17765>

Document downloaded from:



1 **Interpretive Summary**

2 Bolte

3

4 *Staphylococcus aureus* is a common mastitis pathogen in Germany and Denmark. In the pre-
5 sent study, 85 and 93 *S. aureus* isolates from 12 German and 8 Danish dairy farms were tested
6 for their susceptibility to 8 antimicrobials. Thus, MIC values were determined for each iso-
7 late, followed by PCR methods for detecting resistance genes (*blaZ*, *mecA*). Danish *S. aureus*
8 isolates exhibited generally lower MIC₉₀ values concerning most tested β -lactams. A total of
9 5 German isolates carried both resistance genes and one additional isolate carried *blaZ* only.

10 A correlation between predominantly used antimicrobials and reduced susceptibility could not
11 be established.

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27 SUSCEPTIBILITY OF STAPHYLOCOCCUS AUREUS

28

29 **Comparison of phenotypic and genotypic antimicrobial resistance patterns associated**
30 **with *Staphylococcus aureus* mastitis in German and Danish dairy cows**

31

32 **J. Bolte¹, Y. Zhang¹, N. Wente¹, Y. Mahmmod^{2,3,4}, L. Svennesen⁵, V. Krömker^{1,5*}**

33

34 ¹ Department of Microbiology, University of Applied Sciences and Arts, D-30453 Hannover,
35 Germany

36 ² Centre de Recerca en Sanitat Animal (CRESA, IRTA), Universitat Autònoma de Barcelona,
37 Bellaterra, 08193, Barcelona, Spain

38 ³ Veterinary Sciences Division, Al Ain Men's College, Higher Colleges of Technology,
39 17155- Al Ain, Abu Dhabi, United Arab Emirates.

40 ⁴ Infectious Diseases Division, Department of Animal Medicine, Faculty of Veterinary Medi-
41 cine, Zagazig University, 44511-Sharkia, Egypt

42 ⁵ Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences,
43 University of Copenhagen, DK-1870 Frederiksberg C, Denmark

44

45 *corresponding author:

46 Prof. Dr. Volker Krömker

47 Department of Microbiology, University of Applied Sciences and Arts, D-30453 Hannover,
48 Germany.

49 Tel.

50 Fax.

51 Email: Volker.Kroemker@hs-hannover.de

52

ABSTRACT

53
54 *Staphylococcus (S.) aureus* is one of the most common pathogens associated with bovine
55 mastitis in Germany as well as Denmark. A successful therapy is, among others, strongly
56 linked to the susceptibility of the pathogen to the administered antimicrobial. An increase in
57 resistant pathogens in human and veterinary medicine has become a concern worldwide and
58 hampers therapy due to reduced susceptibility. In the present study, susceptibility testing was
59 performed for 85 and 93 *S. aureus* isolates originating from mastitis cases of 12 German and
60 8 Danish dairy farms, respectively. Phenotypic examination was performed by detection of
61 Minimal Inhibitory Concentration (MIC) values using the broth microdilution method, fol-
62 lowed by genotypic investigations of *blaZ* and *mecA* resistance genes via PCR methods. The
63 tested antimicrobials refer to the most frequently used β -lactams in German and Danish dairy
64 farms including cefquinome, cefoperazone, cephapirin, penicillin, oxacillin, cloxacillin,
65 amoxicillin / clavulanic acid and cefalexin / kanamycin. Special attention was paid to varying
66 therapy concepts, since in Germany, third and fourth generation cephalosporins have been
67 predominantly used in mastitis therapy so far, whereas in Denmark, restrictive use of penicil-
68 lin is pursued by a general avoidance of cephalosporins. Differences in MIC values were
69 mainly based on determined MIC₉₀ values. In general, Danish *S. aureus* isolates were inhibit-
70 ed at comparatively lower MIC₉₀ values than *S. aureus* isolated from German dairy farms for
71 most β -lactams. No differences could be observed regarding cefquinome, since both German
72 and Danish isolates exhibited MIC₅₀ and MIC₉₀ values of 0.5 μ g/mL and 1 μ g/mL, respective-
73 ly. In contrast, penicillin MIC₉₀ against German and Danish *S. aureus* was 0.5 μ g/mL and \leq
74 0.06 μ g/mL, respectively. Resistance genes (*blaZ*, *mecA*) were only detected in German *S.*
75 *aureus* isolates on three dairy farms in Germany. A total of 5 isolates were tested positive for
76 both *blaZ* and *mecA*, whereas an individual isolate carried the *blaZ* resistance gene only. A
77 direct correlation between frequently used antimicrobials and reduced susceptibility could not
78 be determined on the basis of the present study. Besides further research for determining fac-

79 tors associated with resistance development, we emphasize the urgent need for internationally
80 standardized clinical breakpoints for assessing resistance situations more accurately.

81

82 **Keywords:** *Staphylococcus aureus*, mastitis, minimum inhibitory concentrations, *blaZ*, *mecA*

INTRODUCTION

83
84 In dairy farming, *Staphylococcus (S.) aureus* plays an important role as a major pathogen of
85 clinical as well as subclinical mastitis. The bovine mastitis is generally treated with β -lactams
86 including the penicillin and cephalosporin groups (Tenhagen et al., 2006; Pol and Ruegg,
87 2007; Ziesch et al., 2018). Resistances to these β -lactams are mainly based on two different
88 resistance mechanisms. One is encoded by the *blaZ* resistance gene and acts via an enzymatic
89 inactivation by β -lactamases. These β -lactamases are capable of attacking the β -lactam ring
90 by hydrolysis, resulting in inactive metabolites. The other one is encoded by the *mecA* gene
91 and induces the formation of an altered penicillin binding protein (PBP) to which antimicro-
92 bials have a greatly reduced affinity and thus lose their efficacy (Schwarz and Chaslus-
93 Dancla, 2001; Wendlandt et al., 2013). A mutual transmission of MRSA between dairy cows
94 and humans, especially those standing in close contact to animals, have further been suspect-
95 ed (Fessler et al., 2012, Lim et al., 2013, Unnerstad et al., 2018). In this context, the European
96 Medicines Agency (EMA) classified antimicrobials according to their risk of resistance de-
97 velopment and special relevance for human health. Thus, use of third and fourth generation
98 cephalosporins (category 2) in veterinary medicine is considered as posing a higher risk to
99 human health than natural penicillins and narrow-spectrum penicillins (category 1) (EMA,
100 2014). In Germany, the total amount of antimicrobial agents dispensed in veterinary medicine
101 decreased by 972.6 tons (57 %) between 2011 and 2017. Whereas the whole group of penicil-
102 lins decreased by 258.9 tons, cephalosporins of all generations remained relatively constant
103 (Wallmann et al., 2018). According to data on antimicrobial intramammary tubes sold in the
104 first quarter of 2017, cefoperazone and cefquinome accounted for more than one third of all
105 antimicrobials relevant in mastitis therapy (unpublished data provided by the Association for
106 Consumer Research (GfK)). Since March 2018, susceptibility testing is required prior to all
107 cases of treatment with third and fourth generation cephalosporins (BMJV, 2018).

108 In contrast, Nordic countries such as Denmark, Norway and Sweden pursue a restrictive an-
109 timicrobial use by avoiding cephalosporins as far as possible. Thus, treatment of *S. aureus*
110 with β -lactamase resistant antimicrobials is just indicated “in cases of severe animal welfare
111 conditions” induced by β -lactamase positive bacteria. Otherwise, only supportive therapy or
112 treatment with penicillin in case of β -lactamase negative pathogens should be first choice of
113 mastitis treatment according to the jointly created “Nordic Guidelines for Mastitis Therapy”
114 (Landin et al., 2011). Moreover, the Danish government established thresholds for antimicro-
115 bial consumption and blanket dry cow therapy is prohibited without bacterial diagnosis be-
116 forehand (Carmo et al., 2017). Denmark thus reduced its overall antimicrobial intake by more
117 than 16 tons between 2013 and 2017 and continuously shifted away from the use of cephalo-
118 sporins. Intramammary antimicrobial therapy is performed by a predominant use of β -
119 lactamase sensitive penicillins and represented 59.8 % of all antimicrobials used for intra-
120 mammary treatment in 2017. The β -lactamase stable penicillins like oxacillin and extended-
121 spectrum penicillins including combinations with β -lactamase inhibitors made up 20.3 % and
122 the cephalosporins 10.5 % of the total. Regarding the latter, the relation of first to third and
123 fourth generation cephalosporins for intramammary application differed with a percentage of
124 96.6 % to 3.4 % (DANMAP, 2018).

125 Due to an obviously contrasting antimicrobial use in mastitis therapy in Germany and Den-
126 mark, the objective of the present study was to identify whether this is reflected in different
127 susceptibility patterns of *S. aureus* as well as considering the presence of *blaZ* and *mecA* re-
128 sistence genes.

129

130

131

MATERIALS AND METHODS

132

133 *Collection of milk samples and microbiological identification of isolates*

134 In the present study, a total of 178 *S. aureus* isolates from intramammary infections of dairy
135 cows were used for susceptibility testing and genotypic investigations. German and Danish
136 farms were representatives of milk producing dairy farms of the respective countries with a
137 predominant use of either cephalosporins of third and fourth generation (Germany) or penicil-
138 lin (Denmark). The 85 German *S. aureus* isolates were randomly selected from the strain col-
139 lection of the University of Applied Sciences and Arts (Hannover, Germany) and originated
140 from quarter foremilk samples that were send to the microbiological laboratory for routine
141 diagnosis. Milk samples were therefore collected between February 2016 and January 2018
142 on 12 dairy farms located in Northern Germany. The herd size of participating dairy farms
143 ranged from 85 to 1325 cows and the Holstein Friesian breed was predominantly kept on
144 Northern German dairy farms. The annual milk production ranged from 8726 to 12353 kg
145 ECM per cow and a bulk tank SCC varying from 87.000 to 328.000 cells/mL.

146 Milk samples from infected quarters of cows suffering from clinical mastitis were taken aseptic-
147 tically in accordance with the guidelines of the German Veterinary Medical Association
148 (2009) by using sterile plastic tubes containing boric acid (Ly20) as a preservative. Immedi-
149 ately after sampling, tubes were cooled below 6 °C and sent to the microbiological laboratory
150 of the University of Applied Sciences and Arts (Hannover, Germany) for etiological diagno-
151 sis. Examinations of samples including cultivation and identification of pathogens were con-
152 ducted in accordance with the methods described by the German Veterinary Medical Associa-
153 tion (2009). A quantity of 10 µL of each milk sample was plated on a quadrant of esculin
154 blood agar (Oxoid Deutschland GmbH, Germany) and incubated at 37 °C under aerobic con-
155 ditions. After 24 and 48 hours of incubation, grown colonies were first investigated concern-
156 ing their morphology and hemolysis patterns. Besides gram staining, examination of cell
157 morphology and catalase activities (3 % H₂O₂; Merck AG, Germany), the clumping factor test

158 (DiaMondiaL Staph Plus Kit, Virotech Diagnostics GmbH, Germany) serves for an initial
159 differentiation of presumptive *S. aureus* isolates. The detection of the *S. aureus*-specific *nuc*
160 gene was performed in accordance with Saiful et al. (2006) and finally confirmed the pres-
161 ence of *S. aureus* in milk samples of intramammary infections (Saiful et al., 2006).

162 A total of 93 *S. aureus* isolates originating from milk samples of dairy cows with subclinical
163 mastitis ($\geq 200,000$ cells/mL) in Danish dairy herds were provided by the University of Co-
164 penhagen (Denmark). Danish *S. aureus* isolates were obtained within the scope of previous
165 research projects investigating contagious mastitis pathogens in Danish dairy herds
166 (Mahmmod et al., 2018; Svennesen et al., 2019). For this purpose, *S. aureus* isolates originat-
167 ing from 8 dairy farms were isolated within the period of February 2017 to April 2017 by
168 project researchers of the University of Copenhagen (Denmark). Between 30 and 40 dairy
169 cows with an elevated SCC ($> 200,000$ cells/mL), but lacking of clinical symptoms, were
170 randomly sampled from each dairy herd. At sampling collection, herd sizes ranged from 198
171 to 344 dairy cows with an estimated milk production between 9,024 and 11,909 kg ECM per
172 cow and a bulk tank SCC ranging from 183,000 to 338,000 cells/mL. Danish Holstein was the
173 predominant breed of all dairy farms, whereby two herds were entirely consisting of Danish
174 Holstein. Sample collection and identification of *S. aureus* including bacterial culturing as
175 well as MALDI-TOF assay were performed and previously described by the project research-
176 ers (Mahmmod et al., 2018; Svennesen et al., 2019). Out of the total number of the harvested
177 *S. aureus* isolates from the projects, 93 isolates were randomly selected to be included in the
178 current study. After identifying all pathogens as *S. aureus*, both German as well as Danish
179 isolates were added to the strain collection of the University of Applied Sciences and Arts
180 (Hannover, Germany) and stored at $- 80$ °C, with the addition of 20 % glycerin, until suscep-
181 tibility testing.

182

183 ***Antimicrobial Susceptibility Testing***

184 The Minimal Inhibitory Concentration (MIC) is a measurement of a pathogen's susceptibility
185 to an antimicrobial agent and is defined as the lowest concentration at which bacterial prolif-
186 eration is no longer visually apparent. Antimicrobial susceptibility testing of 178 *S. aureus*
187 isolates was performed by scientific collaborators of the University of Applied Sciences and
188 Arts in Hannover (Germany). The tested antimicrobial agents were selected on the basis of
189 the substances most frequently used for mastitis therapy in Germany and Denmark, including
190 the following β lactams: cefquinome, cefoperazone, cephalirin, penicillin, oxacillin, cloxacil-
191 lin, amoxicillin / clavulanic acid (4:1) and cefalexin / kanamycin (2:1). The proportion of the
192 tested combinations (amoxicillin / clavulanic acid, cefalexin / kanamycin) referred to the ratio
193 contained in intramammary tubes approved for mastitis treatment. Examination of MIC val-
194 ues was performed using the broth microdilution method in accordance with the DIN
195 58940/ISO20776-1:2006 protocol (DIN, 2007). Polystyrene sterile microtiter plates (Greiner
196 Bio One GmbH, Germany) were used containing a 2-fold dilution series of each antimicrobial
197 substance ranging from 0.06 $\mu\text{g/mL}$ to 32 $\mu\text{g/mL}$.

198 Respective concentration levels were prepared by using Mueller-Hinton-Bouillon (Carl Roth
199 GmbH, Germany) as a liquid nutrient medium. Wells of the microtiter plates finally contained
200 100 μL of an antimicrobial solution to which 5 μL of an immediately prepared bacterial inoc-
201 ulum suspension were added. Positive controls (wells only containing Mueller-Hinton-
202 Bouillon) as well as negative controls (wells without bacterial inoculation) were included in
203 the microtiter plates and *S. aureus* ATCC 29213 (Leibniz Institute DSMZ – German Collec-
204 tion of Microorganisms and Cell Cultures, Germany) was used as a reference strain. After
205 incubating the microtiter plates for 16 to 20 hours at 37 °C, MIC were determinable as wells
206 containing no visible turbidity corresponding to the lowest concentration that inhibits bacteri-
207 al growth.

208

209

210 ***Determination of present blaZ and mecA resistance genes***

211 Extraction of the bacterial DNA was performed by using the DNeasy Blood & Tissue Kit
212 (QIAGEN N.V., the Netherlands). The PCR was carried out in 25 µL reaction mix including
213 12.5 µL ReadyMix Taq PCR Reaction Mix (Sigma-Aldrich GmbH, Germany), 20 pmol of
214 primer, 5 µL of the template and H₂O for no template control. Amplification reactions were
215 performed in a Stratagene Mx3005P qPCR System Thermocycler (Agilent Technologies Inc.,
216 United States). Primers used for detecting resistance genes as well as temperature profiles
217 were programmed as previously described for *blaZ* (Vesterholm-Nielsen et al., 1999) and *mecA*
218 (Saiful et al., 2006). The PCR products were directly stained with Midori Green Direct (Nip-
219 pon Genetics Europe GmbH, Germany) and separated in a 2 % agarose gel at 100 V for 2
220 hours.

221

222

223

RESULTS

224 Results of MIC examinations for *S. aureus* isolates obtained from intramammary infections of
225 dairy cows are presented in detail in Table 1 and Table 2 for 85 German and 93 Danish *S.*
226 *aureus* isolates, respectively. Besides the distribution of isolates according to determined MIC
227 values, MIC₅₀ and MIC₉₀ are given as well (Table 1 and Table 2). MIC₅₀ and MIC₉₀ are de-
228 fined as the lowest concentration where growth of at least 50 % and 90 % of the tested bacte-
229 ria are inhibited, respectively (DIN, 2007). A direct comparison of MIC₅₀ and MIC₉₀ values of
230 German and Danish *S. aureus* isolates is additionally presented in Table 3.

231

232 ***S. aureus obtained from German dairy herds***

233 Due to determined MIC values, the distribution of 85 tested German *S. aureus* isolates was
234 wide for most β-lactams and extended over at least 5 dilution levels with the exception of ce-
235 falexin / kanamycin ranging from 1 µg/mL to 4 µg/mL. The widest distribution pattern was

236 determined for penicillin ranging from ≤ 0.06 mg/mL to 32 mg/mL, without an inhibition of
237 isolates at concentration levels of 1 μ g/mL, 2 μ g/mL and 8 μ g/mL. The highest MIC₅₀ and
238 MIC₉₀ values were 2 μ g/mL and 4 μ g/mL, respectively for cefoperazone as well as for the
239 combination of cefalexin / kanamycin. MIC₉₀ values of cefquinome, cefoperazone and ce-
240 falexin / kanamycin were one dilution higher than their MIC₅₀ values, whereas MIC₉₀ of
241 cephapirin, cloxacillin, oxacillin and amoxicillin / clavulanic acid were 2 dilutions higher than
242 their MIC₅₀ values. The lowest MIC₅₀ value was determined for penicillin, whereas MIC₉₀ of
243 values (0.5 μ g/mL) were lowest for penicillin as well as cephapirin. Since the MIC₅₀ value of
244 penicillin was determined as ≤ 0.06 μ g/mL, the penicillin MIC₉₀ value was at least 3 dilutions
245 higher (Table 1).

246 Within the PCR examination, a total of 5 isolates (5.9 %) were found to be positive for carry-
247 ing *mecA* as well as *blaZ*. Out of these, 4 isolates originated from the same dairy farm (Farm
248 A), whereas a single isolate carrying both resistance genes was isolated from another dairy
249 farm in northern Germany (Farm B). Besides these 5 isolates positive for both *mecA* and
250 *blaZ*, an additional isolate originating from a different farm (Farm C) was identified as posi-
251 tive for *blaZ* only (Table 4).

252 The distribution patterns of isolates originating from farm A and B extended over several di-
253 lution levels of the tested β -lactams. This was based on isolates that carried resistance genes
254 and were inhibited at higher MIC values than another 6 or 7 isolates also obtained from farm
255 A and B, respectively. The single isolate tested positive for *blaZ* solely differed in penicillin
256 MIC values from 6 isolates obtained from farm C as well. Penicillin MIC values were striking
257 different within the same dairy herd and ranged from ≤ 0.06 μ g/mL to 4 μ g/mL (Farm B and
258 C, respectively) or even ≤ 0.06 μ g/mL to 32 μ g/mL (farm A). The distribution of individual
259 isolates received from farm A, B and C did not exceed more than 5 dilution levels. Concern-
260 ing the remaining 9 dairy farms, the number of isolates varied from 1 to 18 isolates per farm,

261 whereby the distribution of isolates did not exceed 3 dilution levels of each antimicrobial
262 agent.

263

264 *S. aureus* obtained from Danish dairy herds

265 The distribution of 93 Danish *S. aureus* isolates was narrow for all kinds of antimicrobials
266 extending over 3 to 5 dilution levels except for cefalexin / kanamycin, since a single isolate
267 exhibited a MIC above the highest concentration tested for this combination ($> 32 \mu\text{g/mL}$).
268 MIC₉₀ values were either one dilution level higher than MIC₅₀ values (cefquinome, cloxacil-
269 lin, oxacillin) or MIC₅₀ and MIC₉₀ values corresponded to the same concentration level
270 (cefoperazone, cephalirin, penicillin, amoxicillin / clavulanic acid, cefalexin / kanamycin). In
271 total, 94.6 % of Danish *S. aureus* had MIC values less or equal to the lowest penicillin con-
272 centration tested ($\leq 0.06 \mu\text{g/mL}$), representing the lowest MIC₅₀ as well as MIC₉₀ values.
273 Highest MIC₅₀ and MIC₉₀ values were determined at a concentration level of $2 \mu\text{g/mL}$ for
274 cefoperazone and cefalexin / kanamycin, respectively.

275 Within genotypic investigations, no isolate originating from Danish dairy farms was positive
276 for carrying *mecA* or *blaZ* resistance genes.

277 *S. aureus* were randomly selected from 8 Danish dairy herds and the total amount per farm
278 varied from 2 to 50 isolates. The widest distribution pattern was apparent for cephalixin /
279 kanamycin due to the *S. aureus* isolate exhibiting a MIC of $> 32 \mu\text{g/mL}$, whereas the remain-
280 ing 17 isolates obtained from the same dairy herd had cefalexin / kanamycin MIC values be-
281 tween $0.5 \mu\text{g/mL}$ and $2 \mu\text{g/mL}$. Oxacillin MIC values of 50 *S. aureus* isolates obtained from
282 one dairy herd showed a distribution ranging over at least 4 dilution levels ($\leq 0.06 \mu\text{g/mL}$ to 1
283 $\mu\text{g/mL}$). In the case of remaining β -lactams, distribution of individual isolates did not exceed
284 more than 3 dilution levels, regardless of which dairy farm they originated from.

285

286

287

DISCUSSION

288 Studies on susceptibility testing of mastitis pathogens are quite rare in both Germany and
289 Denmark. Furthermore, a variety of different methods are available for in vitro susceptibility
290 testing which hinders comparison of these studies. However, the broth microdilution method
291 is considered as the “gold standard” for determining the pathogen’s susceptibility (Constable
292 and Morin, 2003).

293

294 *Susceptibility pattern of S. aureus isolates from German dairy cows*

295 Results of a questionnaire conducted between July 2001 and October 2002 on farms in north-
296 eastern Germany indicated that 35 % of farms used cephalosporins of third (cefoperazone)
297 and fourth (cefquinome) generation for treating clinical mastitis, whereas oxacillin and cloxa-
298 cillin were used in 17 % and penicillin in 13 % of all participating farms (Tenhagen et al.
299 2006).

300 The MIC₉₀ value of oxacillin investigated by Tenhagen and colleagues (2006) was 0.5 µg/mL
301 and is consistent with another German study (BVL, 2017). Even though distribution of iso-
302 lates ranged from 0.06 µg/mL to ≥ 16 µg/mL (BVL, 2017), oxacillin MIC₉₀ in our study was
303 one dilution level higher (1 µg/mL) and in agreement with the study of De Oliveira et al.
304 (2000).

305 Concerning amoxicillin / clavulanic acid, MIC₅₀ and MIC₉₀ values of *S. aureus* were 0.25
306 µg/mL and 0.5 µg/mL, respectively (BVL, 2017). Tenhagen et al. (2006) found MIC₅₀ and
307 MIC₉₀ values of 0.25 µg/mL and 1 µg/mL and thus both MIC values corresponded with our
308 results, even though amoxicillin / clavulanic acid was not used for treating clinical mastitis
309 according to the questionnaire (Tenhagen et al., 2006). In contrast, MIC₅₀ and MIC₉₀ values
310 of amoxicillin / clavulanic acid investigated by De Oliver et al. (2000) were both ≤ 0.06
311 µg/mL.

312 Results of our study were in line with previous trials for both MIC₅₀ and MIC₉₀ values of
313 cefoperazone as well as cefquinome (Tenhagen et al., 2006; BVL, 2017). Moreover, MIC₉₀
314 values of *S. aureus* obtained from intramammary infections were constantly at 1 µg/mL with-
315 in previous resistance monitoring programs (BVL, 2017). However, a German study investi-
316 gating mastitis pathogens from cows with high SCC (> 200,000 cells/mL) detected higher
317 MIC values for cefquinome as well as cephapirin (Wente et al., 2016).

318 In accordance with our study, highest and lowest MIC values among β-lactams tested against
319 *S. aureus* were determined for penicillin (BVL, 2017). In this regard, penicillin MIC₅₀ was
320 0.03 µg/mL, whereas MIC₉₀ of *S. aureus* was 16 µg/mL. Moreover, the distribution of isolates
321 was even wider than examined in our study and ranged from 0.015 µg/mL to > 64 µg/mL,
322 whereby 5 % of all isolates exhibited MIC values above the highest tested concentration (> 64
323 µg/mL). Within the German resistance monitoring program in 2013, MIC₉₀ values of penicil-
324 lin were 2 µg/mL (BVL, 2016) and thus higher than determined for German *S. aureus* in our
325 study (0.5 µg/mL). When comparing results of 2013 and 2015, MIC₉₀ values of penicillin
326 resulted in an 8-fold increase within two years (BVL, 2016; BVL, 2017). Penicillin MIC₅₀
327 and MIC₉₀ values determined by De Oliveira et al. (2000) were coherent with results of Ger-
328 man isolates investigated in our study.

329

330 ***Detection of blaZ and mecA resistance genes in S. aureus from German dairy farms***

331 In our study, resistance genes were detected in German *S. aureus* isolates only, referring to 3
332 dairy farms in Germany (Table 4). The detection of *blaZ* and *mecA* in 4 *S. aureus* isolates
333 obtained from farm A is associated with comparatively higher MIC values. The 4 isolates,
334 which were tested positive for both resistance genes, differed strongly concerning determined
335 MIC values from an additional 6 isolates obtained from Farm A as well: cefquinome (≤ 1
336 µg/mL), cefoperazone (≤ 2 µg/mL), cephapirin (≤ 0.25 µg/mL), penicillin (≤ 0.125 µg/mL),
337 cloxacillin (≤ 1 µg/mL), oxacillin (≤ 1 µg/mL), amoxicillin / clavulanic acid (≤ 0.25 µg/mL).

338 On the one hand, resistance patterns might be spread vertically during replication of the bacte-
339 rial cells. Additionally, *blaZ* as well as *mecA* are located on mobile genetic elements and thus
340 harbour the risk of a horizontal gene transfer between different bacteria (Schwarz and Chas-
341 lus-Dancla, 2001). Based on strongly different MIC values of *S. aureus* isolates from farm A
342 leading to a bimodal distribution pattern, development of a resistant population could be as-
343 sumed within the same dairy farm. However, increased MIC values might be present without
344 existence of resistance genes or vice versa the presence of resistance genes do not necessarily
345 result in increased MIC values (EUCAST, 2018). Several isolates tested negative for *blaZ* and
346 *mecA* were inhibited at equal or higher MIC values than that isolate obtained from farm B
347 tested positive for both resistance genes (Table 1). A discrepancy between phenotypic and
348 genotypic investigations was already described in previous research studies (Haveri et al.,
349 2005; Ruegg et al., 2015; Schmidt et al., 2015). One reason could be a mutation on the an-
350 nealing side of the primer, which subsequently leads to the occurrence of resistances in the
351 absence of identified resistance genes. (Haveri et al., 2005; Schmidt et al. 2015). Another
352 possible explanation might be the presence of additional resistance genes other than *mecA*,
353 which are associated with resistances to β -lactams. In this regard, the *mecA* homologous re-
354 sistance gene *mecC* (former *mecA*_{ALGA251}) could already be detected in MRSA isolated from
355 dairy cows. Although *mecC* is rarely described in German and Danish cows to date (Holmes
356 and Zadoks, 2011; Schlotter et al., 2014; Hansen, 2018), the inclusion of the *mecC* resistance
357 gene in prospective research projects could be important in the future MRSA surveillance. In
358 previous German studies, 3.3 % (BVL, 2017) and 5.9 % (BVL, 2016) were identified as car-
359 rying *mecA*. In comparison to our study (5.9 %), occurrence of *mecA* positive bacteria only
360 referred to individual isolates as well. The occurrence of oxacillin susceptible MRSA (OS-
361 MRSA) was previously described on Chinese (Pu et al., 2014) and Brazilian dairy farms
362 (Guimaraes et al., 2017) and was defined as phenotypical susceptible to oxacillin but carrying
363 *mecA*. *S. aureus* inhibited at oxacillin MIC greater than 4 μ g/mL were classified as oxacillin

364 resistant (Pu et al., 2014; Guimaraes et al., 2017). In this context, the isolate originating from
365 farm B (Table 4) can thus be assumed as OS-MRSA, since oxacillin MIC was 1 µg/mL even
366 though the appearance of *mecA* was determined within PCR examination.

367 Spohr et al. (2011) determined MRSA in German dairy herds with variations between three
368 dairy herds in Germany ranging from 5.1 – 16.7 % (Spohr et al., 2011). Furthermore, Tenha-
369 gen et al. (2018) concluded an increase in the prevalence of MRSA on German dairy farms,
370 since prevalence of MRSA was higher than previously described (Kreausukon et al., 2012;
371 Tenhagen et al., 2014). MRSA in bulk tank milk was thus detectable on conventional and
372 organic dairy farms with 9.7 % and 1.7 %, respectively (Tenhagen et al., 2018).

373

374 ***Susceptibility pattern of S. aureus isolates from Danish dairy farms***

375 Chehabi et al. (2019) currently described the position for penicillin as drug of first choice for
376 mastitis treatment in Denmark as still being favorable. In their study, Chehabi et al. (2019)
377 reported that 82.5 % of all *S. aureus* isolates obtained from clinical mastitis were inhibited at
378 penicillin MIC values of ≤ 0.06 µg/mL (MIC₅₀), while MIC₉₀ of penicillin was determined as
379 2 µg/mL (Chehabi et al., 2019). A previous Danish study in 2003 came to similar results as
380 MIC₅₀ was 0.06 µg/mL and MIC₉₀ was 4 µg/mL (DANMAP, 2004). Both of these studies
381 differed markedly with regard to results for MIC₉₀ of Danish *S. aureus* isolates in our study
382 (Table 2). A study by Sato and colleagues (2004) examined *S. aureus* from bulk tank milk
383 resulting in lower MIC values. Both penicillin MIC₅₀ as well as MIC₉₀ of *S. aureus* from con-
384 ventional farms were ≤ 0.06 µg/mL, whereas MIC₉₀ of *S. aureus* from organic farms was 0.25
385 µg/mL (Sato et al., 2004). Moreover, Sato and colleagues (2004) investigated 100 % of *S.*
386 *aureus* isolates from both organic and conventional farms having oxacillin MIC values of 0.5
387 µg/mL (Sato et al., 2004) which is consistent with our study findings. Results of De Oliveira
388 et al. (2000) were also in line regarding oxacillin MIC values, whereas MIC₅₀ and MIC₉₀

389 values of penicillin were $\leq 0.06 \mu\text{g/mL}$ and $0.25 \mu\text{g/mL}$, respectively (De Oliveira et al.,
390 2000).

391 In Sweden, a country also following the Nordic guidelines for mastitis therapy, restrictive use
392 of preferable penicillin was used in 83 % of all mastitis cases (Landin, 2007) and susceptibil-
393 ity testing of *S. aureus* identified that 92.9 % of all isolates were inhibited at $\text{MIC} \leq 0.12$
394 $\mu\text{g/mL}$ (Bengtsson et al., 2009). This is in agreement with MIC values of penicillin investi-
395 gated in our study for Danish *S. aureus* isolates. MIC_{50} and MIC_{90} values of oxacillin were 1
396 $\mu\text{g/mL}$ and 2 $\mu\text{g/mL}$, respectively (Bengtsson et al., 2009) and thus 2 dilutions higher than
397 those from Danish isolates investigated in our study.

398 Prevalence of resistance genes was rarely described in previous Danish studies on *S. aureus*.
399 Genomic investigation of 63 *S. aureus* isolates from clinical mastitis cases identified 13 (20.6
400 %) as carrying *blaZ* and 1 (1.6 %) as positive for *mecA*. Of the 94 *S. aureus* isolates from
401 bulk tank milk, 14 (14.9 %) were *blaZ* positive, whereas none (0 %) were determined as car-
402 rying *mecA* (Ronco et al., 2018). Other Danish studies detected MRSA in bulk tank milk to
403 the amount of 2 % as *mecA* positive isolates (DANMAP, 2013) and 3 % consisting of seven
404 *mecA* positive *S. aureus* isolates and one *mecC* positive one (Hansen, 2018).

405

406 ***Susceptibility patterns of German and Danish S. aureus with regard to country-specific*** 407 ***antimicrobial use***

408 For at least half of the investigated isolates, country-specific differences in antimicrobial use
409 were not evident due to equal MIC_{50} values of most β -Lactams. With the exception of
410 cefquinome, German *S. aureus* isolates were inhibited at MIC_{90} values that were at least 1
411 concentration level higher than Danish *S. aureus* isolates (Table 3).

412 Differences in phenotypic and genotypic investigations between German and Danish isolates
413 in our study could be due to the generally restrictive use of antimicrobials in Denmark. Ten-
414 hagen et al. (2018) were already able to establish a positive correlation between a strongly

415 limited use of antimicrobial agents on organic farms and the appearance of resistance. Besides
416 the total number of MRSA isolates, antimicrobial resistance to most agents was even more
417 pronounced in isolates obtained from conventional farms (Tenhagen et al., 2018). In contrast,
418 Roesch et al. (2006) identified no significant differences in resistance between mastitis patho-
419 gens isolated from conventional and organic dairy farms. With regard to *S. aureus*, the preva-
420 lence of resistant isolates was even higher in isolates obtained from cows kept on organic
421 farms (35 %) than those obtained from conventional farms (18 %) (Roesch et al., 2006).

422 In Germany in the first quarter of 2017, cefoperazone and cefquinome had market shares of
423 17 % and 22 %, respectively concerning the number of intramammary tubes sold. The most
424 frequently used substance was cefalexin / kanamycin (27 %), whereas the combination of
425 amoxicillin / clavulanic acid accounted for 19 % (unpublished data provided by the Associa-
426 tion for Consumer Research (GfK)). Comparatively higher MIC₉₀ values of German *S. aureus*
427 isolates against cefoperazone, amoxicillin / clavulanic acid and cefalexin / kanamycin (Table
428 3) might thus result from a frequent use on German dairy farms. Selection advantages are
429 considered as the most important events associated with the proliferation of pathogens re-
430 sistant to certain antimicrobials (Barbosa and Levy, 2000).

431 However, results for cefquinome and penicillin contradict this hypothesis. Concerning
432 cefquinome, neither MIC₅₀ nor MIC₉₀ values differed between German and Danish isolates,
433 even though mastitis therapy in Denmark generally refrains from using cephalosporins
434 (Landin, 2011; DANMAP, 2018). Moreover, the susceptibility of udder associated *S. aureus*
435 from German dairy farms to cephalosporins seems to have remained unaltered over the years
436 (BVL, 2017), regardless of the fact that these substances were predominantly used in mastitis
437 treatment for more than 15 years (Tenhagen et al., 2006). On the other hand, penicillin is con-
438 sidered as the drug of first choice for mastitis treatment in Denmark. Nonetheless, within our
439 study, MIC₉₀ of Danish *S. aureus* isolates was determined as $\leq 0.06 \mu\text{g/mL}$ and was thus sub-
440 stantially lower than MIC₉₀ of German *S. aureus* isolates ($0.5 \mu\text{g/mL}$). Within the scope of

441 resistance monitoring programmes, penicillin MIC₉₀ increased to 16 µg/mL (BVL, 2017) by
442 simultaneously reducing penicillin use in mastitis therapy in Germany (Tenhagen et al., 2006;
443 unpublished data provided by the Association for Consumer Research (GfK)). Nevertheless,
444 detection of 20.6 % *blaZ* positive isolates led to the assumption of even higher penicillin re-
445 sistance existing on Danish dairy farms (Ronco et al., 2018).

446 Previous studies examining the correlation between antimicrobial use and resistance of patho-
447 gens draw different conclusions. Saini et al. (2012) found a positive association between pen-
448 icillin resistance in *S. aureus* and intramammary administered penicillin / novobiocin as well
449 as penicillin that was administered systemically (Saini et al., 2012). Pol and Ruegg (2007)
450 determined a correlation between antimicrobial exposure and susceptibility for some Gram-
451 positive pathogen-antimicrobial combinations only. Thus, *S. aureus* showed a reduced sus-
452 ceptibility to penicillin treatment, whereas use of cephalosporins did not result in decreased sus-
453 ceptibility, although it was frequently used as well. An increased exposure of mastitis patho-
454 gens to most antimicrobial substances was not reflected in MIC values (Pol and Ruegg, 2007).
455 Furthermore, Oliver et al. (2011) concluded in a review that routinely used antimicrobials do
456 not result in increased antimicrobial resistance in mastitis pathogens. Even though the fact
457 some drugs have been used for several decades did not lead to a threatening resistance situa-
458 tion of mastitis pathogens (Oliver et al., 2011). Therefore, the influence on the pathogen's
459 susceptibility and the development of resistance seems not to be only dependent on the ad-
460 ministered substance. Pathogen-specific properties associated with *S. aureus*, such as biofilm
461 formation and/ or the invasion of mammary epithelia cells, could additionally hamper the
462 elimination of present pathogens and success of an antimicrobial therapy. Moreover, cows
463 suffering from *S. aureus* induced mastitis cases become frequently chronically infected
464 (Barkema et al., 2006; Taponen and Pyörälä 2009, Rainard et al., 2017). Wente et al. (2016)
465 assumed that increased MIC values might be due to the tendency towards chronicity of sub-
466 clinical mastitis. Dairy cows exhibiting a high SCC might therefore undergo antimicrobial

467 treatment more frequently. Danish *S. aureus* isolates investigated in the current study contra-
468 dict from the assumption of higher MIC values associated with pathogens obtained from sub-
469 clinical mastitis cases. Additionally, results of Oliveira et al. (2012) did also not provide a
470 general statement about susceptibility of *S. aureus* from clinical or subclinical mastitis cases
471 due to strong variations in MIC values of isolates, regardless of their particular origin
472 (Oliveira et al., 2012). A more likely influencing factor for the development of resistances
473 might be the frequency of antimicrobial treatments. This is also in line with investigations of
474 Rajala-Schultz et al. (2004), which detected higher resistances in older cows and attributed
475 this to an increased exposure to antimicrobial treatments (Rajala-Schultz et al., 2004). Fur-
476 thermore, since Denmark generally limits the antimicrobial use in mastitis therapy as much as
477 possible, this could be the probable explanation for lower MIC values of Danish *S. aureus*
478 from subclinical mastitis cases. Nevertheless, further research focusing on the relation be-
479 tween antimicrobial use and occurrence of resistance would be a meaningful tool in the future
480 for detecting relevant influencing factors.

481 Recommendations for therapy derived from susceptibility testing of pathogens are usually
482 carried out on the basis of specific breakpoints used for classifying isolates into clinically re-
483 sistant, intermediate and susceptible. According to clinical breakpoints previously used to
484 categorize *S. aureus* from intramammary infections (Thomas et al., 2015; De Jong et al.,
485 2018; Käppeli et al., 2019), two (2.2 %) and another single (1.1 %) Danish *S. aureus* could be
486 classified as resistant to penicillin and cefalexin / kanamycin, respectively. Furthermore, the
487 breakpoints indicate low resistances of German *S. aureus* isolates to penicillin (11.8 %), oxa-
488 cillin (4.7 %), cloxacillin (0 %), cephapirin (0 %) amoxicillin / clavulanic acid (0 %) and ce-
489 falexin / kanamycin (0 %). From this point of view, an urgent need for using critically im-
490 portant cephalosporins could not be established, since various antimicrobial agents are con-
491 sidered as appropriate alternatives. However, the validity of this statement is limited by sever-
492 al aspects that need to be considered in the discussion of resistances of mastitis pathogens.

493 First of all, methodology and interpretative criteria need to follow the same susceptibility test-
494 ing guidelines for an accurate assessment (Schwarz et al., 2010). Moreover, clinical break-
495 points for cefquinome and cefoperazone are still lacking, whereas breakpoints for remaining
496 β -lactams were not mastitis-specific. The Clinical and Laboratory Standards Institute (CLSI)
497 published clinical breakpoints for 3 antimicrobial agents related to the indication mastitis:
498 ceftiofur, penicillin / novobiocin and pirlimycin (Ruegg et al., 2015). These antimicrobial
499 agents are either not approved for intramammary therapy or they are not relevant in mastitis
500 treatment in Germany or Denmark (DANMAP 2018; Wallmann et al. 2018; unpublished data
501 provided by the Association for Consumer Research (GfK)). Absence of specific clinical
502 breakpoints for mastitis indication leads to a transfer of breakpoints established for different
503 indications, other animal species or human medicine. The statement concerning the present
504 resistance situation and especially recommendations for therapy resulting from such a classi-
505 fication are questionable. Haveri et al. (2005) also hypothesized that discrepancies in genotyp-
506 ic and phenotypic investigations could be due to the use of improper clinical breakpoints. This
507 problem was largely avoided in our study by focusing rather on MIC values and distribution
508 patterns of the isolates. The dosage achieved at the site of infection varies depending on the
509 tissue and thus does not reflect the concentration reached in the mammary gland. For instance,
510 β -lactams achieve a high concentration in the urine and breakpoints based on urinary tract
511 infections might thus be set higher. A transmission of those breakpoints to mastitis pathogens
512 is inappropriate and can lead to misinterpretations (Rossitto et al., 2002; Schwarz et al.,
513 2010). For this reason, we emphasize the need to establish internationally standardized clini-
514 cal breakpoints in order to adequately assess the resistance situation and derive effective rec-
515 ommendations for mastitis therapy.

516

517

CONCLUSION

518 In conclusion, the German *S. aureus* isolates investigated in the present study were inhibited
519 at comparatively higher MIC₉₀ values for most β -lactams than *S. aureus* isolates from Danish
520 dairy farms. *BlaZ* and *mecA* resistance genes were isolated in individual German *S. aureus*
521 isolates only and were generally associated with occurrence of comparatively higher MIC
522 values. The predominant use of either penicillin in Denmark or cephalosporins of third
523 (cefoperazone) and fourth (cefquinome) generation in Germany were not directly reflected in
524 determined MIC values. Results further lead to the assumption that development of resistance
525 is not solely dependent on the administered substance. Further research focusing on the inter-
526 actions of antimicrobial use and development of resistance would be appropriate for determin-
527 ing decisive influencing factors and for establishing suitable preventive measures. Therapy
528 recommendations deriving from the results of the present study are not directly transferable to
529 in vivo practice or derived therapy recommendations, thus highlighting the need for interna-
530 tionally standardized clinical breakpoints.

531

532

ACKNOWLEDGMENTS

533 We would like to thank the University of Copenhagen (Denmark) for supporting our study by
534 providing Danish *S. aureus* isolates.

535

536

CONFLICT OF INTEREST

537 No conflict of interest.

538

539

REFERENCES

540 Barbosa, T. M. and S. B. Levy. 2000. The impact of antibiotic use on resistance development
541 and persistence. *Drug Resist Updat* 3(5):303-311.
542 <https://doi.org/10.1054/drup.2000.0167>.

543 Barkema, H., Y. Schukken, and R. Zadoks. 2006. Invited review: The role of cow, pathogen,
544 and treatment regimen in the therapeutic success of bovine *Staphylococcus aureus*
545 mastitis. *Journal of dairy science* 89(6):1877-1895. [https://doi.org/10.3168/jds.S0022-](https://doi.org/10.3168/jds.S0022-0302(06)72256-1)
546 [0302\(06\)72256-1](https://doi.org/10.3168/jds.S0022-0302(06)72256-1).

547 Bengtsson, B., H. E. Unnerstad, T. Ekman, K. Artursson, M. Nilsson-Ost, and K. P. Waller.
548 2009. Antimicrobial susceptibility of udder pathogens from cases of acute clinical
549 mastitis in dairy cows. *Vet Microbiol* 136(1-2):142-149.
550 <https://doi.org/10.1016/j.vetmic.2008.10.024>.

551 BMJV (Bundesministerium der Justiz und für Verbraucherschutz). 2018. Verordnung über
552 tierärztliche Hausapotheken (TÄHAV). Access April 12, 2018. [http://www.gesetze-im-](http://www.gesetze-im-internet.de/t_hav/T%C3%84HAV.pdf)
553 [internet.de/t_hav/T%C3%84HAV.pdf](http://www.gesetze-im-internet.de/t_hav/T%C3%84HAV.pdf).

554 BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit). 2016. Berichte zur
555 Resistenzmonitoringstudie - Resistenzsituation bei klinisch wichtigen tierpathogenen
556 Bakterien 2012/2013. Springer International Publishing AG Schwitserland, Basel.
557 <http://dx.doi.org/10.1007/978-3-319-31697-0>.

558 BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit). 2017. Berichte zur
559 Resistenzmonitoringstudie - Resistenzsituation bei klinisch wichtigen tierpathogenen
560 Bakterien 2014/2015. Springer International Publishing AG Schwitserland, Basel. Ac-
561 cess February 02, 2018.
562 [https://www.bvl.bund.de/SharedDocs/Downloads/09_Untersuchungen/Archiv_bericht](https://www.bvl.bund.de/SharedDocs/Downloads/09_Untersuchungen/Archiv_berichte_Resistenzmonitoring/Resistenz-Monitoring-2014-2015.pdf?__blob=publicationFile&v=2)
563 [e_Resistenzmonitoring/Resistenz-Monitoring-2014-](https://www.bvl.bund.de/SharedDocs/Downloads/09_Untersuchungen/Archiv_berichte_Resistenzmonitoring/Resistenz-Monitoring-2014-2015.pdf?__blob=publicationFile&v=2)
564 [2015.pdf?__blob=publicationFile&v=2](https://www.bvl.bund.de/SharedDocs/Downloads/09_Untersuchungen/Archiv_berichte_Resistenzmonitoring/Resistenz-Monitoring-2014-2015.pdf?__blob=publicationFile&v=2).

565 Carmo, L. P., L. R. Nielsen, L. Alban, C. R. Muntener, G. Schupbach-Regula, and I. Magour-
566 as. 2017. Comparison of Antimicrobial Consumption Patterns in the Swiss and Danish
567 Cattle and Swine Production (2007-2013). *Front Vet Sci* 4:26.
568 <https://doi.org/10.3389/fvets.2017.00026>.

569 Chehabi, C. N., B. Nonnemann, L. B. Astrup, M. Farre, and K. Pedersen. 2019. In vitro An-
570 timicrobial Resistance of Causative Agents to Clinical Mastitis in Danish Dairy Cows.
571 Foodborne Pathog Dis 16(8):562-572. <https://doi.org/10.1089/fpd.2018.2560>.

572 Constable, P. D. and D. E. Morin. 2003. Treatment of clinical mastitis: Using antimicrobial
573 susceptibility profiles for treatment decisions. Veterinary Clinics: Food Animal Prac-
574 tice 19(1):139-155. [https://doi.org/10.1016/S0749-0720\(02\)00068-3](https://doi.org/10.1016/S0749-0720(02)00068-3).

575 DANMAP (Danish Integrated Antimicrobial Resistance Monitoring and Research Pro-
576 gramme). 2004. DANMAP 2003 - Use of antimicrobial agents and occurrence of an-
577 timicrobial resistance in bacteria from food animals, foods and humans in Denmark.,
578 Accessed January 25, 2018. <https://www.danmap.org/downloads/reports>.

579 DANMAP (Danish Integrated Antimicrobial Resistance Monitoring and Research Pro-
580 gramme). 2013. DANMAP 2012 - Use of antimicrobial agents and occurrence of an-
581 timicrobial resistance in bacteria from food animals, foods and humans in Denmark.
582 Accessed January 25, 2018. <https://www.danmap.org/downloads/reports>.

583 DANMAP (Danish Integrated Antimicrobial Resistance Monitoring and Research Pro-
584 gramme). 2018. DANMAP 2017 - Use of antimicrobial agents and occurrence of an-
585 timicrobial resistance in bacteria from food animals, foods and humans in Denmark.
586 Accessed January 25, 2018. <https://www.danmap.org/downloads/reports>.

587 De Oliveira, A., J. Watts, S. Salmon, and F. M. Aarestrup. 2000. Antimicrobial susceptibility
588 of Staphylococcus aureus isolated from bovine mastitis in Europe and the United
589 States. Journal of Dairy Science 83(4):855-862. [https://doi.org/10.3168/jds.S0022-
590 0302\(00\)74949-6](https://doi.org/10.3168/jds.S0022-0302(00)74949-6).

591 de Jong, A., F. El Garch, S. Simjee, H. Moyaert, M. Rose, M. Youala, E. Siegart, and V. S.
592 Group. 2018. Monitoring of antimicrobial susceptibility of udder pathogens recovered
593 from cases of clinical mastitis in dairy cows across Europe: VetPath results.
594 Veterinary microbiology 213:73-81. <https://doi.org/10.1016/j.vetmic.2017.11.021>.

595 DIN (Deutsches Institut für Normung e.V.). 2007. Clinical laboratory testing and in vitro di-
596 agnostic test systems – Susceptibility testing of infectious agents and evaluation of
597 performance of antimicrobial susceptibility test devices – Part 1: Reference method for
598 testing the in vitro activity of antimicrobial agents against rapidly growing aerobic
599 bacteria involved in infectious diseases (ISO 20776-1:2006); German version EN ISO
600 20776-1:2006, Beuth Verlag GmbH, Berlin.

601 EUCAST (European Committee on Antimicrobial Susceptibility Testing). 2018. EUCAST
602 General Consultation on “Considerations in the numerical estimation of epidemiologi-
603 cal cutoff (ECOFF) values”. Accessed Mai 09, 2018.
604 http://www.eucast.org/mic_distributions_and_ecoffs.

605 EMA. 2014. Answers to the requests for scientific advice on the impact on public health and
606 animal health of the use of antibiotics in animals – Answer to the second request from
607 the EC (ranking of antibiotics); Answer to the third request from the EC (new antibiot-
608 ics); Answer to the fourth request from the EC (risk mitigation options)
609 (EMA/381884/2014).

610 Fessler, A. T., R. G. Olde Riekerink, A. Rothkamp, K. Kadlec, O. C. Sampimon, T. J. Lam,
611 and S. Schwarz. 2012. Characterization of methicillin-resistant *Staphylococcus aureus*
612 CC398 obtained from humans and animals on dairy farms. *Vet Microbiol* 160(1-2):77-
613 84. <https://doi.org/10.1016/j.vetmic.2012.05.005>.

614 German Veterinary Medical Association, 2009. Leitlinien Entnahme von Milchproben unter
615 antiseptischen Bedingungen und Isolierung und Identifizierung von Mastitiserregern,
616 2nd ed. Verlag der Deutschen Veterinärmedizinischen Gesellschaft, Gießen.

617 Guimaraes, F. F., M. P. Manzi, S. F. Joaquim, V. B. Richini-Pereira, and H. Langoni. 2017.
618 Short communication: Outbreak of methicillin-resistant *Staphylococcus aureus*
619 (MRSA)-associated mastitis in a closed dairy herd. *J Dairy Sci* 100(1):726-730.
620 <https://doi.org/10.3168/jds.2016-11700>.

621 Hansen J. E. 2018. Methicillin-resistant *Staphylococcus aureus* in Danish production animals.
622 PhD Thesis. National Veterinary Institute, Division of Diagnostics & Scientific Ad-
623 vice – Bacteriology & Parasitology, Technical University of Denmark.

624 Haveri, M., S. Suominen, L. Rantala, T. Honkanen-Buzalski, and S. Pyörälä. 2005.
625 Comparison of phenotypic and genotypic detection of penicillin G resistance of
626 *Staphylococcus aureus* isolated from bovine intramammary infection. *Veterinary*
627 *microbiology* 106(1-2):97-102. <https://doi.org/10.1016/j.vetmic.2004.12.015>.

628 Holmes, M. A. and R. N. Zadoks. 2011. Methicillin resistant *S. aureus* in human and bovine
629 mastitis. *Journal of mammary gland biology and neoplasia* 16(4):373-382.
630 <https://doi.org/10.1007/s10911-011-9237-x>.

631 Käppeli, N., M. Morach, S. Corti, C. Eicher, R. Stephan, and S. Johler. 2019. *Staphylococcus*
632 *aureus* related to bovine mastitis in Switzerland: Clonal diversity, virulence gene
633 profiles, and antimicrobial resistance of isolates collected throughout 2017. *Journal of*
634 *dairy science* 102(4):3274-3281. <https://doi.org/10.3168/jds.2018-15317>.

635 Kreausukon, K., A. Fetsch, B. Kraushaar, K. Alt, K. Muller, V. Kromker, K. H. Zessin, A.
636 Kasbohrer, and B. A. Tenhagen. 2012. Prevalence, antimicrobial resistance, and mo-
637 lecular characterization of methicillin-resistant *Staphylococcus aureus* from bulk tank
638 milk of dairy herds. *J Dairy Sci* 95(8):4382-4388. [https://doi.org/10.3168/jds.2011-](https://doi.org/10.3168/jds.2011-5198)
639 [5198](https://doi.org/10.3168/jds.2011-5198).

640 Landin, H., J. Carlsson, J. Katholm, L. Kulkas, K. Plym-Forsell, E. Rattenborg, C. Sandgren,
641 L. Solverod, C. Whist. 2011. Nordic guidelines for mastitis therapy. The Swedish
642 Dairy Association. Accessed March 15, 2018.
643 [http://www.sva.se/globalassets/redesign2011/pdf/antibiotika/antibiotikaresistens/nordi](http://www.sva.se/globalassets/redesign2011/pdf/antibiotika/antibiotikaresistens/nordic-guidelines-for-mastitis-therapy.pdf)
644 [c-guidelines-for-mastitis-therapy.pdf](http://www.sva.se/globalassets/redesign2011/pdf/antibiotika/antibiotikaresistens/nordic-guidelines-for-mastitis-therapy.pdf).

645 Landin, H. 2007. Mastitis treatment in Swedish Milk Production. Page 11 in Animal farming
646 in transition - the role of animal reproduction: Mastitis symposium, St Petersburg State
647 Academy of Veterinary Medicine, Russia. CRU Report 19, Uppsala.

648 Lim, S. K., H. M. Nam, G. C. Jang, H. S. Lee, S. C. Jung, and T. S. Kim. 2013. Transmission
649 and persistence of methicillin-resistant *Staphylococcus aureus* in milk, environment,
650 and workers in dairy cattle farms. *Foodborne Pathog Dis* 10(8):731-736.
651 <https://doi.org/10.1089/fpd.2012.1436>.

652 Mahmmud, Y. S., I. C. Klaas, L. Svennesen, K. Pedersen, and H. Ingmer. 2018. Communica-
653 tions of *Staphylococcus aureus* and non-aureus *Staphylococcus* species from bovine
654 intramammary infections and teat apex colonization. *J Dairy Sci* 101(8):7322-7333.
655 <https://doi.org/10.3168/jds.2017-14311>.

656 Oliveira, L., H. Langoni, C. Hulland, and P. Ruegg. 2012. Minimum inhibitory concentrations
657 of *Staphylococcus aureus* recovered from clinical and subclinical cases of bovine
658 mastitis. *Journal of dairy science* 95(4):1913-1920. <https://doi.org/10.3168/jds.2011-4938>.

660 Oliver, S. P., S. E. Murinda, and B. M. Jayarao. 2011. Impact of antibiotic use in adult dairy
661 cows on antimicrobial resistance of veterinary and human pathogens: a comprehensive
662 review. *Foodborne Pathog Dis* 8(3):337-355. <https://doi.org/10.1089/fpd.2010.0730>.

663 Pol, M. and P. Ruegg. 2007. Relationship between antimicrobial drug usage and antimicrobial
664 susceptibility of gram-positive mastitis pathogens. *Journal of dairy science* 90(1):262-
665 273. [https://doi.org/10.3168/jds.S0022-0302\(07\)72627-9](https://doi.org/10.3168/jds.S0022-0302(07)72627-9).

666 Pu, W., Y. Su, J. Li, C. Li, Z. Yang, H. Deng, and C. Ni. 2014. High incidence of oxacillin-
667 susceptible *mecA*-positive *Staphylococcus aureus* (OS-MRSA) associated with bovine
668 mastitis in China. *PLoS One* 9(2):e88134.
669 <https://doi.org/10.1371/journal.pone.0088134>.

670 Rainard, P., G. Foucras, J. R. Fitzgerald, J. Watts, G. Koop, and J. Middleton. 2018.
671 Knowledge gaps and research priorities in *Staphylococcus aureus* mastitis control.
672 *Transboundary and emerging diseases* 65:149-165.
673 <https://doi.org/10.1111/tbed.12698>.

674 Rajala-Schultz, P., K. Smith, J. Hogan, and B. Love. 2004. Antimicrobial susceptibility of
675 mastitis pathogens from first lactation and older cows. *Veterinary microbiology* 102(1-
676 2):33-42. <https://doi.org/10.1016/j.vetmic.2004.04.010>.

677 Ruegg, P., L. Oliveira, W. Jin, and O. Okwumabua. 2015. Phenotypic antimicrobial
678 susceptibility and occurrence of selected resistance genes in gram-positive mastitis
679 pathogens isolated from Wisconsin dairy cows. *Journal of dairy science* 98(7):4521-
680 4534. <https://doi.org/10.3168/jds.2014-9137>.

681 Roesch, M., V. Perreten, M. Doherr, W. Schaeren, M. Schällibaum, and J. Blum. 2006. Com-
682 parison of antibiotic resistance of udder pathogens in dairy cows kept on organic and
683 on conventional farms. *Journal of Dairy Science* 89(3):989-997.
684 [https://doi.org/10.3168/jds.S0022-0302\(06\)72164-6](https://doi.org/10.3168/jds.S0022-0302(06)72164-6)

685 Ronco, T., I. C. Klaas, M. Stegger, L. Svennesen, L. B. Astrup, M. Farre, and K. Pedersen.
686 2018. Genomic investigation of *Staphylococcus aureus* isolates from bulk tank milk
687 and dairy cows with clinical mastitis. *Vet Microbiol* 215:35-42.
688 <https://doi.org/10.1016/j.vetmic.2018.01.003>.

689 Rossitto, P., L. Ruiz, Y. Kikuchi, K. Glenn, K. Luiz, J. Watts, and J. S. Cullor. 2002. Antibio-
690 tic susceptibility patterns for environmental streptococci isolated from bovine masti-
691 tis in central California dairies. *Journal of dairy science* 85(1):132-138.
692 [https://doi.org/10.3168/jds.S0022-0302\(02\)74061-7](https://doi.org/10.3168/jds.S0022-0302(02)74061-7).

693 Saiful, A. J., M. Mastura, S. Zarizal, M. I. Mazurah, M. Shuhaimi, and A. M. Ali. 2006. De-
694 tection of Methicillin-Resistant *Staphylococcus aureus* Using *mecA/nuc* Genes and
695 Antibiotic Susceptibility Profile of Malaysian Clinical Isolates. *World Journal of Mi-*

696 crobiology and Biotechnology 22(12):1289-1294. <https://doi.org/10.1007/s11274-006->
697 9174-9.

698 Saini, V., J. T. McClure, D. T. Scholl, T. J. DeVries, and H. W. Barkema. 2012. Herd-level
699 association between antimicrobial use and antimicrobial resistance in bovine mastitis
700 *Staphylococcus aureus* isolates on Canadian dairy farms. *J Dairy Sci* 95(4):1921-1929.
701 <https://doi.org/10.3168/jds.2011-5065Get>.

702 Sato, K., T. W. Bennedsgaard, P. Bartlett, R. Erskine, and J. Kaneene. 2004. Comparison of
703 antimicrobial susceptibility of *Staphylococcus aureus* isolated from bulk tank milk in
704 organic and conventional dairy herds in the midwestern United States and Denmark.
705 *Journal of food protection* 67(6):1104-1110. <https://doi.org/10.4315/0362-028X->
706 [67.6.1104](https://doi.org/10.4315/0362-028X-67.6.1104).

707 Schlotter, K., R. Huber-Schlenstedt, A. Gangl, H. Hotzel, S. Monecke, E. Müller, A. Reißig,
708 S. Proft, and R. Ehricht. 2014. Multiple cases of methicillin-resistant CC130
709 *Staphylococcus aureus* harboring *mecC* in milk and swab samples from a Bavarian
710 dairy herd. *Journal of dairy science* 97(5):2782-2788.
711 <https://doi.org/10.3168/jds.2013-7378>.

712 Schmidt, T., M. M. Kock, and M. M. Ehlers. 2015. Diversity and antimicrobial susceptibility
713 profiling of staphylococci isolated from bovine mastitis cases and close human
714 contacts. *Journal of dairy science* 98(9):6256-6269. <https://doi.org/10.3168/jds.2015->
715 [9715](https://doi.org/10.3168/jds.2015-9715).

716 Schwarz, S. and E. Chaslus-Dancla. 2001. Use of antimicrobials in veterinary medicine and
717 mechanisms of resistance. *Veterinary research* 32(3-4):201-225.
718 <https://doi.org/10.1051/vetres:2001120>.

719 Schwarz, S., P. Silley, S. Simjee, N. Woodford, E. van Duijkeren, A. P. Johnson, and W.
720 Gastra. 2010. Assessing the antimicrobial susceptibility of bacteria obtained from an-
721 imals. *Vet Microbiol* 141(1-2):1-4. <https://doi.org/10.1016/j.vetmic.2009.12.013>.

722 Spohr, M., J. Rau, A. Friedrich, G. Klittich, A. Fetsch, B. Guerra, J. A. Hammerl, and B. A.
723 Tenhagen. 2011. Methicillin-resistant *Staphylococcus aureus* (MRSA) in three dairy
724 herds in southwest Germany. *Zoonoses Public Health* 58(4):252-261.
725 <https://doi.org/10.1111/j.1863-2378.2010.01344.x>.

726 Svennesen, L., S. S. Nielsen, Y. S. Mahmmud, V. Kromker, K. Pedersen, and I. C. Klaas.
727 2019. Association between teat skin colonization and intramammary infection with
728 *Staphylococcus aureus* and *Streptococcus agalactiae* in herds with automatic milking
729 systems. *J Dairy Sci* 102(1):629-639. <https://doi.org/10.3168/jds.2018-15330>.

730 Taponen, S. and S. Pyorala. 2009. Coagulase-negative staphylococci as cause of bovine
731 mastitis- not so different from *Staphylococcus aureus*? *Vet Microbiol* 134(1-2):29-36.
732 <https://doi.org/10.1016/j.vetmic.2008.09.011>.

733 Thomas, V., A. de Jong, H. Moyaert, S. Simjee, F. El Garch, I. Morrissey, H. Marion, and M.
734 Vallé. 2015. Antimicrobial susceptibility monitoring of mastitis pathogens isolated
735 from acute cases of clinical mastitis in dairy cows across Europe: VetPath results.
736 *International journal of antimicrobial agents* 46(1):13-20.
737 <https://doi.org/10.1016/j.ijantimicag.2015.03.013>.

738 Tenhagen, B.-A., G. Köster, J. Wallmann, and W. Heuwieser. 2006. Prevalence of mastitis
739 pathogens and their resistance against antimicrobial agents in dairy cows in Branden-
740 burg, Germany. *Journal of Dairy Science* 89(7):2542-2551.
741 [https://doi.org/10.3168/jds.S0022-0302\(06\)72330-X](https://doi.org/10.3168/jds.S0022-0302(06)72330-X).

742 Tenhagen, B. A., K. Alt, B. Pfefferkorn, L. Wiehle, A. Kasbohrer, and A. Fetsch. 2018. Short
743 communication: Methicillin-resistant *Staphylococcus aureus* in conventional and or-
744 ganic dairy herds in Germany. *J Dairy Sci* 101(4):3380-3386.
745 <https://doi.org/10.3168/jds.2017-12939>.

746 Tenhagen, B. A., B. Vossenkuhl, A. Kasbohrer, K. Alt, B. Kraushaar, B. Guerra, A.
747 Schroeter, and A. Fetsch. 2014. Methicillin-resistant *Staphylococcus aureus* in cattle

748 food chains - prevalence, diversity, and antimicrobial resistance in Germany. *J Anim*
749 *Sci* 92(6):2741-2751. <https://doi.org/10.2527/jas.2014-7665>.

750 Unnerstad, H. E., K. Mieziowska, S. Borjesson, H. Hedback, K. Strand, T. Hallgren, H.
751 Landin, J. Skarin, and B. Bengtsson. 2018. Suspected transmission and subsequent
752 spread of MRSA from farmer to dairy cows. *Vet Microbiol* 225:114-119.
753 <https://doi.org/10.1016/j.vetmic.2018.09.017>.

754 Vesterholm-Nielsen, M., M. L. Olhom, J. O. Elmerdahl, and F. A. Moller. 1999. Occurrence
755 of the blaZ gene in penicillin resistant *Staphylococcus aureus* isolated from bovine
756 mastitis in Denmark. *Acta veterinaria Scandinavica* 40(3):279-286.

757 Wallmann J., C. Bode, A. Bender, T. Heberer. 2018. Abgabemengenerfassung von
758 Antibiotika in Deutschland 2017. *Deutsches Tierärzteblatt* 66 (9):1238-1247.

759 Wendlandt, S., A. T. Fessler, S. Monecke, R. Ehricht, S. Schwarz, and K. Kadlec. 2013. The
760 diversity of antimicrobial resistance genes among staphylococci of animal origin. *Int J*
761 *Med Microbiol* 303(6-7):338-349. <https://doi.org/10.1016/j.ijmm.2013.02.006>.

762 Wente, N., V. Zoche-Golob, M. Behr, and V. Kromker. 2016. Susceptibility to cephalosporins
763 of bacteria causing intramammary infections in dairy cows with a high somatic cell
764 count in Germany. *Prev Vet Med* 131:146-151.
765 <https://doi.org/10.1016/j.prevetmed.2016.06.010>.

766 Ziesch, M., N. Wente, Y. Zhang, W. Zaremba, S. Engl, and V. Kromker. 2018. Noninferiority
767 trial investigating the efficacy of a nonantibiotic intramammary therapy in the treat-
768 ment of mild-to-moderate clinical mastitis in dairy cows with longer lasting udder dis-
769 eases. *J Vet Pharmacol Ther* 41(1):11-21. <https://doi.org/10.1111/jvp.12415>.

770

771

772

773

774 **Table 1.** Distribution of MIC of *S. aureus* (n = 85) isolated from 12 German dairy farms¹

Agent	Distribution of MIC (µg/mL)										
	≤ 0.06	0.125	0.25	0.5	1	2	4	8	16	32	> 32
Cefquinome	-	-	4	<i>40</i>	35	5	1	-	-	-	-
Cefoperazone	-	-	-	19	12	33	15	2	4	-	-
Cephapirin	22	<i>31</i>	21	6	1	3	1	-	-	-	-
Penicillin	<i>64</i>	11	1	3	-	-	2	-	3	1	-
Cloxacillin	1	15	<i>30</i>	27	8	4	-	-	-	-	-
Oxacillin	-	13	33	22	12	1	1	3	-	-	-
AMC ²	5	31	27	11	5	6	-	-	-	-	-
CFX / K ³	-	-	-	-	2	56	27	-	-	-	-

775

776 ¹ MIC₅₀ and MIC₉₀ are displayed in italics and bold, respectively.

777 ² Amoxicillin / clavulanic acid.

778 ³ Cefalexin / kanamycin.

779

780

781

782 **Table 2.** Distribution of MIC of *S. aureus* (n = 93) isolated from 8 Danish dairy farms¹

Antimicrobial	Distribution of MIC ($\mu\text{g/mL}$)										
	≤ 0.06	0.125	0.25	0.5	1	2	4	8	16	32	> 32
Cefquinome	-	-	3	55	34	1	-	-	-	-	-
Cefoperazone	-	-	-	10	23	54	6	-	-	-	-
Cephapirin	16	28	49	-	-	-	-	-	-	-	-
Penicillin	88	3	2	-	-	-	-	-	-	-	-
Cloxacillin	-	18	56	18	1	-	-	-	-	-	-
Oxacillin	1	15	47	28	2	-	-	-	-	-	-
AMC ²	-	24	63	6	-	-	-	-	-	-	-
CFX / K ³	-	-	-	10	3	71	7	1	-	-	1

783
784 ¹ MIC₅₀ and MIC₉₀ are displayed in italics and bold, respectively. Bold and italic digits indi-
785 cate that MIC₅₀ and MIC₉₀ were identical.

786 ² Amoxicillin / clavulanic acid.

787 ³ Cefalexin / kanamycin.

788

789

790

791 **Table 3.** MIC₅₀ (µg/mL) and MIC₉₀ (µg/mL) of German (n = 85) and Danish (n = 93) *S. aure-*
 792 *us* isolates

Antimicrobial	MIC ₅₀ / MIC ₉₀ (µg/mL)	Germany (n = 85)	Denmark (n = 93)
Cefquinome	MIC ₅₀	0.5	0.5
	MIC ₉₀	1	1
Cefoperazone	MIC ₅₀	2	2
	MIC ₉₀	4	2
Cephapirin	MIC ₅₀	0.125	0.25
	MIC ₉₀	0.5	0.25
Penicillin	MIC ₅₀	≤ 0.06	≤ 0.06
	MIC ₉₀	0.5	≤ 0.06
Cloxacillin	MIC ₅₀	0.25	0.25
	MIC ₉₀	1	0.5
Oxacillin	MIC ₅₀	0.25	0.25
	MIC ₉₀	1	0.5
Amoxicillin / clavulanic acid	MIC ₅₀	0.25	0.25
	MIC ₉₀	1	0.25
Cefalexin / kanamycin	MIC ₅₀	2	2
	MIC ₉₀	4	2

794 **Table 4.** MIC values ($\mu\text{g/mL}$) of *S. aureus* isolates carrying *blaZ* and *mecA* ($n = 5$) and *blaZ*
 795 ($n = 1$) from 3 German dairy farms

Resistance genes ¹	Dairy farm	MIC ($\mu\text{g/mL}$)							
		CEQ ²	CEFO ³	CPR ⁴	PEN ⁵	CLO ⁶	OXA ⁷	AMC ⁸	CFX/K ⁹
<i>blaZ</i> + / <i>mecA</i> +	A	1	16	2	16	2	8	2	4
	A	4	16	2	32	2	8	2	4
	A	2	16	4	16	1	4	2	4
	A	2	16	2	16	2	8	2	4
	B	0.5	8	1	4	0.5	1	2	4
<i>blaZ</i> + / <i>mecA</i> -	C	0.5	4	0.25	4	0.25	0.5	1	2

796
 797 ¹ “+” and “-“ indicate a positive or negative result of resistance genes (*blaZ*, *mecA*), respec-
 798 tively.

799 ² Cefquinome.

800 ³ Cefoperazone.

801 ⁴ Cephapirin.

802 ⁵ Penicillin.

803 ⁶ Cloxacillin.

804 ⁷ Oxacillin.

805 ⁸ Amoxicillin / clavulanic acid.

806 ⁹ Cefalexin / kanamycin.

807

808